Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M106783200 on July 19, 2001

J. Biol. Chem., Vol. 276, Issue 38, 35589-35598, September 21, 2001
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/38/35589    most recent
M106783200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lu, B.
Right arrow Articles by Fantus, I. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lu, B.
Right arrow Articles by Fantus, I. G.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Enhanced Sensitivity of Insulin-resistant Adipocytes to Vanadate Is Associated with Oxidative Stress and Decreased Reduction of Vanadate (+5) to Vanadyl (+4)*

Bing Lu, David EnnisDagger, Robert Lai, Elena Bogdanovic, Rinna Nikolov, Lisa Salamon, Claire Fantus, Hoang Le-Tien, and I. George Fantus§

From the Department of Medicine, Mount Sinai Hospital, Banting and Best Diabetes Centre and Department of Physiology, University of Toronto, Toronto, Ontario M5G 1X5, Canada

Received for publication, July 18, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Vanadate (sodium orthovanadate), an inhibitor of phosphotyrosine phosphatases (PTPs), mimics many of the metabolic actions of insulin in vitro and in vivo. The potential of vanadate to stimulate glucose transport independent of the early steps in insulin signaling prompted us to test its effectiveness in an in vitro model of insulin resistance. In primary rat adipocytes cultured for 18 h in the presence of high glucose (15 mM) and insulin (10-7 M), sensitivity to insulin-stimulated glucose transport was decreased. In contrast, there was a paradoxical enhanced sensitivity to vanadate of the insulin-resistant cells (EC50 for control, 325 ± 7.5 µM; EC50 for insulin-resistant, 171 ± 32 µM; p < 0.002). Enhanced sensitivity was also present for vanadate stimulation of insulin receptor kinase activity and autophosphorylation and Akt/protein kinase B Ser-473 phosphorylation consistent with more effective PTP inhibition in the resistant cells. Investigation of this phenomenon revealed that 1) depletion of GSH with buthionine sulfoximine reproduced the enhanced sensitivity to vanadate while preincubation of resistant cells with N-acetylcysteine (NAC) prevented it, 2) intracellular GSH was decreased in resistant cells and normalized by NAC, 3) exposure to high glucose and insulin induced an increase in reactive oxygen species, which was prevented by NAC, 4) EPR (electron paramagnetic resonance) spectroscopy showed a decreased amount of vanadyl (+4) in resistant and buthionine sulfoximine-treated cells, which correlated with decreased GSH and increased vanadate sensitivity, while total vanadium uptake was not altered, and 5) inhibition of recombinant PTP1B in vitro was more sensitive to vanadate (+5) than vanadyl (+4). In conclusion, the parodoxical increased sensitivity to vanadate in hyperglycemia-induced insulin resistant adipocytes is due to oxidative stress and decreased reduction of vanadate (+5) to vanadyl (+4). Thus, sensitivity of PTP inhibition and glucose transport to vanadate is regulated by cellular redox state.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Insulin resistance of glucose transport is a well documented characteristic of type 2 diabetes mellitus (1-3). The etiology of the insulin resistance appears to be multifactorial since it is found in subjects with obesity, those with impaired glucose tolerance, as well as in those with overt type 2 diabetes. There is evidence that both genetic and acquired factors contribute to the insulin resistance (4-6). In type 2 diabetic subjects, peripheral target tissue insulin resistance is characterized by defects in both sensitivity, manifested as a rightward shift in the insulin dose-response curve, and responsiveness, a decrease in maximum response (7-9). This combination of defects has been reproduced in vitro in isolated rat adipocytes incubated for several hours in the presence of a combination of high glucose and high insulin concentrations (10). In this in vitro model, defects in insulin stimulation of glucose transport and glucose transporter translocation are prominent, similar to that found in adipocytes isolated from subjects with type 2 diabetes (9-12).

The signaling pathway by which insulin stimulates glucose transport is only partially understood. Insulin binds to its receptor (IR)1 and activates its intrinsic Tyr kinase, resulting in phosphorylation of the receptor and its substrates, IRS-1 and -2 (13-15). These, in turn, act as docking proteins for several SH2 domain-containing proteins such as Grb2, SH2 domain-containing phosphatase-2, and p85 (13-16). Binding of the SH2 domains of the p85 subunit of PI 3-kinase results in activation of the p110 catalytic subunit and the generation of the lipid products phosphatidylinositol 3,4,5-trisphosphate and phosphatidylinositol 3,4-bisphosphate (16, 17). These lipids facilitate phosphoinositide-dependent kinase-1- and -2-mediated phosphorylation of several substrate enzymes such as PKB (Akt/RAC-PK) and atypical protein kinase C zeta  and lambda  (18-21). The requirement for the IR, IRS 1/2, PI 3-kinase, and either or both PKB and atypical protein kinase Cs for glucose transport stimulation by insulin is well documented, whereas less is known about the more distal signaling events (9, 13-15, 22-24).

Vanadate (+5) and vanadyl (+4) compounds have been well documented to mimic many of the actions of insulin (25-28). Glucose uptake and metabolism are stimulated in fat and muscle tissue (29, 30), lipolysis is inhibited (31), and hepatic glucose output is suppressed (32, 33). Oral administration of vanadate and vandyl resulted in lowering of glucose concentrations in rodent models of both type 1 and type 2 diabetes (34-37). Recent studies in human diabetic subjects suggest that these vanadium compounds can lower glycemia and improve lipid levels (38, 39), whereas this treatment was less effective in improving insulin resistance in nondiabetic obese subjects (40).

The mechanism by which vanadate mimics insulin is not completely clear. Although protein-tyrosine phosphatase (PTP) inhibition appears to be important, the role of the IR and/or other Tyr kinases remains controversial (41-43). In some studies, IR kinase activation by vanadate has been documented (44, 45). However, it has been found that insulin-mimetic effects can be stimulated independent of any IR activation (41, 42, 46). The activation of cytosolic (47) and membrane-associated (49) low molecular weight tyrosine kinases have been linked with some of these metabolic effects. However, since these associations were based on inhibition by staurosporine, which inhibits a wide spectrum of kinases, their role remains unclear. In other studies, glucose transport stimulation by vanadate, in contrast to that stimulated by insulin, was found to be independent of the enzymes PI 3-kinase (49, 50) and PKB (50). These data raised the possibility that vanadium compounds may have a unique ability to stimulate and/or enhance insulin metabolic effects in some states of insulin resistance.

To determine the efficacy of vanadate to stimulate glucose transport in an insulin resistant target tissue, we examined its actions in the insulin-resistant rat adipocyte model induced by high glucose and insulin. We found that there was a paradoxical enhanced sensitivity of glucose uptake to vanadate in the insulin-resistant cells, i.e. a leftward shift in the vanadate dose-response curve. This was associated with a concomitant enhanced sensitivity of the insulin-resistant cells to vanadate-stimulated Tyr phosphorylation of the IR and of its intrinsic Tyr kinase activity as well as Ser-473 phosphorylation of the downstream kinase PKB. Investigation of the possible mechanism showed that there was a greater intracellular concentration of vanadate (+5) relative to vanadyl (+4) in the insulin-resistant adipocytes. In vitro studies showed that inhibition of PTP1B phosphatase activity was more sensitive to vanadate (+5) than vanadyl (+4). These data demonstrate that vanadate (+5) is a more potent PTP inhibitor than vanadyl (+4) and that there is decreased reduction of vanadate (+5) to vanadyl (+4) in the insulin-resistant adipocytes. They are also consistent with our observations of increased generation of reactive oxygen species (ROS) in adipocytes exposed to high glucose and insulin and of the influence of altered cellular levels of GSH (glutathione) on vanadate sensitivity

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Male Harlan Sprague-Dawley rats were from Charles River (St. Constant, Quebec, Canada). Dulbecco's modified Eagle's medium (DMEM), penicillin, streptomycin, and fetal bovine serum were from Life Technologies, Inc. Type I collagenase was from Worthington Biochemical Corp. (Freehold, NJ). Human insulin was a gift from Eli Lilly (Indianapolis, IN). 2-deoxy-D-[3H]glucose (10 Ci/mmol) was from PerkinElmer Life Sciences (Mississauga, Ontario, Canada). The GSH assay kit was from Calbiochem (La Jolla, CA). Nitex nylon was from Thompson (Scarborough, ON). 5,6-Carboxy-22,72-dichlorofluorescein-diacetate (DCF-DA) was from Molecular Probes (Eugene, OR). Bovine serum albumin (fraction V), buthionine sulfoximine (BSO), sodium orthovanadate (vanadate), and N-acetylcysteine (NAC) were from Sigma. Vanadyl sulfate was from BD PharMingen (Mississauga, Ontario, Canada). Anti-Tyr(P) antibody (PY20) was from UBI (Lake Placid, NY) anti-PKB and anti-phosphoserine 473-PKB antibodies were from Cell Signaling Technology (Beverly, MA), and anti-IR antibody was a kind gift from Dr. C. Yip (University of Toronto, Toronto, Ontario, Canada) or from Santa Cruz.

Preparation of Isolated Adipocytes-- Male Harlan Sprague-Dawley rats weighing 180-200 g were gassed with O2/CO2, killed by cervical dislocation, and epididymal fat pads collected in 3% BSA-DMEM. Adipocytes were isolated as described (51). In brief, adipose tissue was incubated in 3% BSA-DMEM containing 2 mg/ml collagenase for 1 h at 37 °C. Cells were then filtered through Nitex nylon (1000 µm), centrifuged at 500 rpm for 30 s, and washed twice with 3% and then 1% BSA-DMEM to remove collagenase.

Primary Culture and Induction of Insulin Resistance-- The isolated adipocytes were incubated in 1% BSA-DMEM (pH 7.4) supplemented with 0.5% fetal bovine serum and 25 mM HEPES, 1% antibiotics in 250-ml conical culture flasks at 37 °C with cells floating on top of the medium in a thin layer. Cells were incubated for 18 h in a humidified atmosphere of 5% CO2 and air. To induce insulin resistance, 10-7 M insulin and 15 mM D-glucose (final concentrations) were added to the medium. Control cells contained no added insulin, and final glucose concentration was 5.6 mM. Cells treated with buthionine sulfoximine (BSO) were incubated in control medium supplemented with 80 µM BSO. Preliminary experiments revealed that this concentration was nontoxic by visual assessment of adipocyte integrity, by trypan blue exclusion, as well as by maintenance of basal and insulin-stimulated glucose uptake similar to that in control cells. The NAC treatment of insulin-resistant adipocytes was carried out with a 2-h pre-exposure of cells to 30 mM NAC at 37 °C prior to the induction of insulin resistance for 18 h as described above. After the 18-h incubation, cells were washed twice in 3% BSA-KR30H, pH 7.0 (137 mM NaCl, 5 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 1.25 mM CaCl2, 30 mM HEPES, 1 mM sodium pyruvate, and 3% BSA), and then further incubated in the same buffer for an additional 30 min at 37 °C to remove any remaining receptor-bound insulin. Cells were then resuspended in 3% BSA-KRBH, pH 7.4 (118 mM NaC1, 5 mM KCl, 1.2 mM MgSO4, 2.5 mM CaCl2, 1.2 mM KH2PO4, 5 mM NaHCO3, 30 mM HEPES, 1 mM sodium pyruvate, and 3% BSA) and washed twice in the same buffer before 2-deoxyglucose (2-DG) uptake assay.

2-Deoxyglucose Uptake-- The 2-DG uptake assay was performed as described previously (52) with minor modifications. Adipocytes (5 × 105 cells/ml) were preincubated at 37 °C with vanadate concentrations from 0 to 2 mM for 60 min. Initial rates of glucose uptake were measured by adding 1 µCi of 2-deoxy-D-[3H]glucose and unlabeled 2-DG (final substrate concentration, 100 µM) to a final volume of 500 µl. At the end of 3 min, the reaction was terminated by adding 500 µl of ice-cold 0.25 mM phloretin. Nonspecific uptake mediated by simple diffusion and trapping was determined by measuring [3H]2-DG uptake in the presence of 0.25 mM phloretin and was subtracted from total uptake to yield specific uptake. In each experiment, glucose uptake was derived from the mean of duplicate determinations.

IR Autophosphorylation in Situ-- After 18 h of incubation and washing as described above, adipocytes were incubated at 37 °C in KRBH in the presence of the indicated concentrations of vanadate for 30 min. The reaction was terminated by immediate freezing to -70 °C in liquid N2 followed by the addition of ice-cold solubilization buffer (1% Triton X-100, 4 mM EDTA, 2 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 1 trypsin inhibitor unit/ml of aprotinin, 1 mM vanadate, and 30 mM HEPES, pH 7.6). Adipocytes were homogenized and solubilized for an additional 1 h at 4 °C. After removal of the fat cake by centrifugation at 1800 × g for 10 min, the cell extract was centrifuged further at 100,000 × g for 1 h at 4 °C. The supernatant was applied to a 1 ml column of WGA-agarose and the IRs eluted with 50 mM HEPES buffer, pH 7.6, containing 150 mM NaCl, 0.1% Triton X-100, and 0.3 M N-acetyl-D-glucosamine. 125I-Insulin binding to the lectin purified extract was performed as described previously (53). In some experiments IRs were immunoprecipitated from the solubilized adipocyte extracts with anti-IR antibody.

Equal amounts of IR from the WGA-purified fractions or immunoprecipitates were subjected to SDS-PAGE under reducing conditions. After electrophoretic transfer to nitrocellulose membranes the latter were washed and blocked with PBS, pH 7.4, containing 10% fetal bovine serum for 1 h at 22 °C. The immunoblotting with anti-Tyr(P) and anti-IR was performed as described previously (45) except that in some experiments the secondary antibodies were conjugated with horseradish peroxidase and detection was with ECL (Amersham Pharmacia Biotech).

Insulin Receptor Tyrosine Kinase Activity-- A procedure similar to that reported previously was followed (45, 53). Lectin-purified IRs (10-20 fmol of insulin binding) were placed in a buffer at 22 °C containing 50 mM HEPES, 1 mM MnCl2, 15 mM MgSO4, 2.5 mg/ml poly(Glu-Tyr) (4:1), and 25 µM [gamma -32P]ATP (5 µCi/tube, pH 7.6) in a total volume of 160 µl. After 10 min, the reaction was terminated by spotting 100 µl of the reaction mixture on filter paper, which was then placed in 10% trichloroacetic acid containing 10 mM sodium pyrophosphate. After extensive washing in this solution, the paper was dried and placed in 20 ml of Aquasol-II for determination of radioactivity.

Phosphorylation of PKB-- The extent of Ser-473 phosphorylation of PKB was determined as described previously (50). Cell lysates (50 µg) were subjected to SDS-PAGE (10%) followed by electrotransfer to nitrocellulose membranes (Schleicher & Schuell). After blocking for 1 h at 22 °C in Tris-buffered saline, pH 7.5, containing 0.1% Tween 20 and 5% nonfat dry milk, the membranes were incubated overnight with a 1:1000 dilution of either the anti-phospho-PKB antibody or anti-PKB. The membranes were washed and treated for 1 h with secondary antibody (1:10000) conjugated to horseradish peroxidase (Amersham Pharmacia Biotech). Proteins were visualized by ECL (Amersham Pharmacia Biotech).

Determination of Cellular GSH-- After the 18-h incubation, the different groups of adipocytes were washed and 5 ml of packed cells were resuspended in an equal volume of 5% metaphosphoric acid. After homogenization using a Teflon pestle, the homogenate was centrifuged at 3000 × g for 10 min at 4 °C. The resulting supernatant (100 µl) was used for the GSH assay, which was performed according to the procedure provided by the manufacturer (Calbiochem).

Detection of ROS-- Adipocytes were prepared and added to the various culture conditions described above. DCF-DA (20 µM final concentration) was added at time 0, and the incubation continued at 37 °C. At the times indicated, a 1-ml aliquot of cell suspension was removed, resuspended in 0.5 ml of PBS, and subjected to flow cytometry analysis (Epics Elite cell sorter, Beckman-Coulter) using an excitatory wavelength of 488 nm and detection wavelength of 525 nm (range, 500-545). The mean fluorescence intensity of 10,000 cells from each sample was determined. Signals detected from cells incubated in the absence of probe were considered as background and subtracted. Exposure of adipocytes to H2O2 was used as a positive control. Dead cells and debris were excluded by electronic gating of forward and side scatter measurements (54).

Electron Paramagnetic Resonance (EPR) Spectroscopy-- After the 18-h incubation, the different groups of cells were washed and incubated with 1 mM vanadate in 3% BSA-KRBH for 120 min. At the end of the incubation, samples were centrifuged and the infranatant buffer was removed. Three hundred µl of packed cells were pipetted into 500-µl glass tubes, which were flushed with N2. The tubes were inserted directly into the Bruker TE102 pre-cooled cavity by means of a Teflon sample holder. EPR spectra were collected using a Bruker ECS-106 spectrometer equipped with a model B-VT2000 temperature controller. Liquid N2 was used to maintain the temperature of the sample, which was measured to an accuracy of ± 0.1 K with a chromium-alumel thermocouple located in the glass Dewar and positioned just below the cavity. The EPR measurements were performed at 223 K.

The EPR instrument parameters were as follows: microwave frequency, 9.4 GHz; microwave power, 25.0 milliwatts; magnetic field, 3365 ± 1000 G; modulation frequency, 50 Hz; modulation amplitude, 8 G. Scanning interval of the magnetic field ranged from 1000 to 1200 G. The EPR spectra parameters were determined by the ECS-106 Bruker data manipulation program. The temperature was chosen to increase the sensitivity and stability of the measurements of rapidly oxidizing paramagnetic centers in biological samples.

Determination of Total Intracellular Vanadium Concentration-- After the 18-h incubation, the different groups of cells were washed and incubated for 0-120 min in the presence of 1 mM vanadate in 3% BSA-KRBH. At the times indicated, the adipocytes were washed five times with PBS made up in double distilled (dd) de-ionized H2O at 22 °C. In preliminary experiments we determined that there was no vanadium detectable in the fourth or fifth washes after adipocytes were exposed to up to 10 mM vanadate. The cells were separated by centrifugation, and 100-µl aliquots were digested overnight at 23 °C in 100 µl of concentrated (60%) nitric acid. The solubilized supernatant was diluted 50 times in dd de-ionized water. Total vanadium concentrations were determined by atomic absorption spectrometry (55). A standard curve was measured using vanadate dissolved in 0.1% nitric acid made with dd de-ionized water.

Determination of PTP Inhibition-- Sodium orthovanadate was dissolved in water and was stored at -20 °C. Vanadyl sulfate was dissolved in water just prior to use to limit oxidation, and N2 was bubbled through all solutions to prevent oxidation.

Recombinant glutathione S-transferase/PTP-IB (GST/PTP-1B) fusion protein bound to glutathione-agarose beads (Upstate Biotechnology Inc., Lake Placid, NY) was washed three times with Buffer A (100 mM HEPES, pH 7.5, 2 mM DTT, and 150 mM NaCl). The GST/PTP-1B fusion protein was then resuspended at a concentration of 1.25 ng/µl in Buffer A supplemented with 125 µg/ml BSA. Five µl of vanadate or vanadyl solution (final assay concentration of 0-4000 mM) were placed in the wells of a flat-bottomed, 96-well plate (Corning). Twenty µl of Buffer A was added followed by 20 µl (25 µg) of GST/PTP-1B suspension, and the plate was gently shaken. To begin the reaction, 5 µl of 2 mM pp60c-src C-terminal phosphoregulatory peptide (TSTEPQpYQPGENL) or 5 µl of 1 mM IR beta -subunit phosphoregulatory peptide (TRDIpYETDpYpYRK) (Biomol, Plymouth Meeting, PA) were added for a total volume of 50 µl/well. Following a 10-min incubation on a rotator at 22 °C, determined to be in the linear range, the reaction was stopped by adding 100 µl of Biomol Green reagent and the release of Pi determined by measuring the absorbance at 630 nm using a Titertek Plus 96-well plate reader. Neither vanadate nor vanadyl (up to 4 mM) interfered with the detection of Pi.

To determine the effect of DTT on the inhibitors, the above procedure was followed except that Buffer A contained the desired concentration of DTT (0-1.6 mM). Controls were compared at each concentration of DTT.

Definition of Terms and Statistical Analyses-- Results are expressed as percentage above basal. Sensitivity of glucose uptake was determined from the vanadate dose-response curves normalized from basal (0%) to maximum (100%) uptake. IC50 curves were produced using GraphPad Prism 3.0 for Windows 95 (GraphPad Software, San Diego, CA). Quantitative differences among treatment groups were assessed by calculating and comparing the half-maximally effective vanadate concentration (EC50). All values in the text and figures are presented as means ± S.E. All data were subjected to analysis of variance. Probabilities of 0.05 or less were considered to be statistically significant.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Enhanced Sensitivity to Vanadate of Glucose Uptake in Insulin-resistant Adipocytes-- The generation of insulin resistance by exposure of freshly isolated rat adipocytes to a medium containing high concentrations of glucose and insulin (high G/I) has been well documented (10, 11). We have determined that this results in a decrease in both responsiveness and sensitivity to insulin. Thus maximum stimulation by insulin after 18-h exposure to high G/I was decreased by 38% (control, 306 ± 20.4 pmol/8 × 105 cells/3 min; resistant cells, 189 ± 24.4; p < 0.01), and the concentration of insulin required to stimulate glucose uptake to 50% of maximum, a measure of sensitivity, was increased in the resistant cells (control, 0.12 ± .01 nM; resistant cells, 0.34 ± 0.10 nM; p < 0.05) (data not shown).

In contrast to insulin, when adipocytes cultured in the high G/I medium (resistant cells) were stimulated with vanadate, there was a paradoxical enhanced sensitivity of the resistant cells compared with control. (Note that, throughout these studies, resistant cells refers to adipocytes treated with high G/I and rendered insulin-resistant.) Thus, the vanadate dose-response curve was left-shifted and the concentration of vanadate required for half-maximum stimulation of glucose uptake was 325 ± 7.5 µM in control and 171 ± 32 µM in resistant cells (n = 5, p < 0.002) (Fig. 1). The maximum response to vanadate tended to be lower but was not significantly decreased in the resistant cells (Fig. 1).


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 1.   Enhanced sensitivity of glucose transport to vanadate in insulin-resistant adipocytes. Freshly isolated rat adipocytes were cultured for 18 h at 37 °C in DMEM containing 5.6 mM glucose (control, ) or 15 mM glucose supplemented with 10-7 M insulin (resistant cells, open circle ). The adipocytes were harvested and washed to remove glucose and insulin and allow recovery to basal glucose uptake. The cells were resuspended in 3% BSA-KRBH buffer and vanadate-stimulated [3H]2-DG uptake assayed. Upper panel, stimulation above basal (designated as 100%). Results are mean ± S.E. (n = 5). Lower panel, data are plotted as percentage of maximum. Sensitivity to vanadate of the insulin-resistant adipocytes was significantly increased manifested by the leftward shift in the dose-response curve (see "Results" for details). *, p < 0.05; **, p < 0.01.

Enhanced Sensitivity of the IR to Vanadate in Insulin-resistant Adipocytes-- Since the mechanism by which vanadate stimulates glucose uptake appears to involve inhibition of PTPs and subsequent stimulation of Tyr phosphorylation, we examined the ability of vanadate to activate the IR kinase and induce Tyr phosphorylation of the IR. Control and insulin-resistant adipocytes were exposed to vanadate (0-1 mM) for 30 min and IRs extracted and partially purified by WGA chromatography. It should be noted that exposure to vanadate concentrations up to 5 mM did not result in greater maximum IR Tyr phosphorylation or kinase activity than observed at 1 mM in either control or resistant adipocytes (data not shown). The insulin-resistant adipocytes showed a paradoxical increased sensitivity of IR kinase activation by vanadate. The concentration of vanadate required to activate the IR kinase to 50% of maximum was 100 µM in control cells and 26 µM in resistant cells (Fig. 2). The maximum activation of the IR kinase was achieved at 1 mM vanadate and was not significantly different (control, 2.11 ± 0.44 pmol of 32P incorporated/fmol of IR; resistant cells, 1.85 ± 0.44; n = 4) (Table I). We noted that maximum IR kinase activity stimulated by vanadate ranged from 35 to 50% of that achieved by maximum insulin (data not shown).


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 2.   Stimulation of the IR kinase by vanadate in rat adipocytes. Rat adipocytes were prepared as described and cultured for 18 h at 37 °C in control medium () and medium containing high glucose (15 mM) and insulin (10-7 M) (open circle ). After washing, the adipocytes were incubated in the presence and absence of 0-1 mM vanadate for 30 min. The adipocytes were solubilized, IRs partially purified by WGA chromatography and kinase activity assayed using poly(Glu-Tyr) (4:1) as substrate as described under "Experimental Procedures." Values are mean ± S.E. of three to four separate experiments. The vanadate dose-response curve was shifted to the left in the insulin-resistant adipocytes (see "Results" for details). *, p < 0.05.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Insulin receptor kinase activity stimulated by vanadate
Adipocytes were cultured in DMEM with 5.6 mM glucose (Control) or containing 15 mM glucose and 10-7 M insulin (Resistant). After 18 h at 37 °C, cells were washed and stimulated with vanadate. IRs were partially purified by WGA chromatography and equal aliquots (125I-insulin binding) assayed for kinase activity using poly(Glu-Tyr) (4:1) as described under "Experimental Procedures." Values are mean ± S.E. (n = 4). The maximum insulin-stimulated IRK activity was 5.13 ± 0.99.

Activation of the IR kinase is associated with IR Tyr autophosphorylation. To determine whether the enhanced sensitivity of the IR kinase to vanadate in the resistant adipocytes was correlated with IR Tyr phosphorylation, the receptors were subjected to immunoblotting with anti-Tyr(P) antibodies. The dose-dependent phosphate incorporation onto Tyr residues of the IR corrected for total IR showed a significantly greater sensitivity to vanadate in the resistant cells (control versus resistant dose-response, p < 0.001) (Fig. 3). The concentration of vanadate that stimulated 50% of maximum IR Tyr phosphorylation was 66 µM in control and 15 µM in resistant cells. These concentrations were similar to those obtained for activation of the IR kinase above. Maximum Tyr(P) incorporation corrected for IR beta -subunit was not different in control and resistant cells (Fig. 3).


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 3.   Enhanced sensitivity of insulin-resistant adipocytes to vanadate stimulation of IR phosphorylation. Rat adipocytes were isolated, cultured overnight, washed, and stimulated with vanadate as described in Fig. 2. Equal amounts of WGA-purified IRs were separated by SDS-PAGE and immunoblotted (IB) with anti-Tyr(P) (pY) and anti-IR beta -subunit antibodies. A, representative immunoblot of dose-dependent IR Tyr phosphorylation by vanadate in control and insulin-resistant adipocytes. B, anti-IR beta -subunit immunoblot of A. C, normalized vanadate dose-response curves of IR Tyr(P) corrected for IR beta -subunit in control () and resistant (open circle ) adipocytes. Values are mean ± S.E. of three independent experiments. The two curves were significantly different (p < 0.001, analysis of variance).

Increased Sensitivity of PKB to Vanadate in Insulin-resistant Adipocytes-- Tyr phosphorylation of the IR and its activation leads to phosphorylation of substrates such as the IRS proteins and subsequent activation of a number of signaling molecules (13, 14). Among these the Ser kinase PKB is prominent and has been implicated in insulin-dependent glucose transport (20-22). Since both IR activation and glucose transport were both more sensitive to vanadate in the insulin-resistant cells, we measured PKB phosphorylation. In the insulin-resistant cells, PKB Ser-473 phosphorylation was more sensitive to vanadate (Fig. 4). PKB Ser-473 phosphorylation has been demonstrated to reflect enzymatic activity in response to insulin (18-20) and vanadium compounds (50).


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 4.   Enhanced sensitivity of insulin-resistant adipocytes to vanadate stimulation of PKB phosphorylation. Rat adipocytes were isolated and cultured as described in Fig. 2. After stimulation with 0-10 mM vanadate, whole cell lysates were prepared and 50 µg of protein separated by SDS-PAGE, transferred to membranes, and immunoblotted with anti-phospho-Ser-473-PKB (A) and anti-PKB (B). C, the intensities of the bands from three independent experiments were quantified by densitometry and corrected for total PKB. The maximum values for control () (designated as 100%) and resistant (open circle ) (93.5 ± 0.07%) cells were not significantly different. Normalized dose-response curves are shown and indicate that resistant cells were more sensitive to vanadate. *, p < 0.05.

Enhanced Sensitivity to Vanadate Is Mimicked by BSO and Reversed by NAC-- It has been demonstrated that vanadate (+5) is reduced to vanadyl (+4) once it enters cells (56, 57). This appears to be mediated, at least in part, by GSH to which vanadyl can bind (57, 58). However, the oxidized form, vanadate (+5), has been proposed to be more efficacious as a PTP inhibitor than vanadyl (59, 60) and stable complexes of vanadate bound to the active site of PTPs have been successfully crystallized (61). This is consistent with the bipyramidal structure of vanadate, which closely resembles phosphate (61, 62). We hypothesized that the enhanced sensitivity to vanadate in these insulin-resistant adipocytes may be secondary to a decrease in the intracellular reduction of vanadate (+5) to vanadyl (+4). To address this possibility, rat adipocytes were cultured for 18 h in the presence of BSO, which inhibits the rate-limiting enzyme of GSH synthesis, gamma -glutamylcysteine synthetase, following which vanadate-stimulated glucose uptake was measured. Treatment of rat adipocytes with 80 µM BSO resulted in an enhanced sensitivity to vanadate even greater than that observed in the insulin-resistant cells. The stimulation of 2-DG uptake was significantly increased in BSO-treated cells compared with control at vanadate concentrations from 10 to 500 µM (Fig. 5A). The concentrations of vanadate required for half-maximal stimulation of glucose transport (EC50) in these experiments were 205 µM in control, 110 µM in-resistant cells, and 30 µM in BSO-treated cells, respectively (Fig. 5A).


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of BSO and NAC on sensitivity of adipocytes to vanadate. Rat adipocytes were prepared as described and incubated for 18 h in control medium (Control, ), medium containing 15 mM glucose and 10-7 M insulin (Resistant (R), open circle ) and medium containing 80 µM BSO (BSO, triangle ). Additional aliquots of adipocytes were pretreated for 2 h with 30 mM NAC prior to the 18 h incubation in high glucose/high insulin containing medium (R + NAC, black-square). The adipocytes were washed and vanadate-stimulated [3H]DG uptake assayed as described in Experimental Procedures. Basal and maximum 2-DG uptake were not significantly different (data not shown). A, the normalized vanadate dose-response curves showed a leftward shift in resistant cells, indicating increased sensitivity in resistant cells (similar to results in Fig. 1) and a more marked increase in sensitivity in cells pretreated with BSO. Asterisks are shown on control () compared with resistant cells, resistant cells (open circle ) compared with BSO, BSO (triangle ) compared with control (analysis of variance). B, normalized vanadate dose-response curves in resistant adipocytes pre-treated (black-square) or not (open circle ) with NAC. Pretreatment with NAC prevented the leftward shift such that sensitivity to vanadate remained similar to controls. Pretreatment with NAC of control cells had no effect on the vanadate dose response (data not shown). Values are the mean ± S.E. of four to eight separate experiments. *, p < 0.05; **, p < 0.01; ***, p < 0.001.

NAC is a known free radical scavenger that can also promote GSH synthesis by supplying the precursor cysteine (63, 64). To avoid any direct effects of NAC, adipocytes were pretreated for 2 h at 37 °C with 30 mM NAC, washed, and then cultured overnight under the conditions described above. NAC pretreatment of cells exposed to high G/I restored the sensitivity to vanadate to that observed in control (EC50, 200 µM) (Fig. 5B). Neither BSO nor NAC pretreatment alone altered the maximum stimulation of 2-DG uptake by vanadate (data not shown).

Effect of High G/I, BSO, and NAC on Intracellular GSH-- In order to determine whether the intracellular GSH concentrations were perturbed in the above experiments, adipocytes were incubated and cultured as described above, lysed, and GSH measured. As expected, treatment with the GSH synthesis inhibitor BSO markedly reduced GSH concentrations (control, 328 ± 21.2 µM; BSO-treated, 91 ± 17.8 µM; p < 0.001). Interestingly, the GSH concentration was also significantly decreased in the insulin-resistant adipocytes, i.e. after 18 h of exposure to high G/I, GSH levels were 167 ± 5.6 µM (p < 0.001 compared with control). Pretreatment of the high G/I exposed cells with 30 mM NAC for 2 h prevented the fall in GSH concentration (325 ± 18.6 µM, p = not significant compared with control) (Fig. 6).


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 6.   Effect of high glucose plus insulin, BSO, and NAC on adipocyte GSH. Rat adipoyctes were prepared, treated, and cultured under the conditions described in Fig. 4. After 18 h the cells were washed, resuspended in 5% metaphosphoric acid, homogenized, and GSH concentration measured as described under "Experimental Procedures." Values are mean ± S.E. of three to five separate experiments performed in duplicate. C, control; R, resistant cells; BSO, buthionine sulfoximine; R+NAC, resistant cells pretreated with N-acetylcysteine. ***, p < 0.001 compared with control and resistant cells pretreated with N-acetylcysteine.

Increased ROS Production Induced by High G/I-- A decrease in intracellular GSH concentration is an indirect indication of oxidative stress, i.e. the generation of ROS in excess of the antioxidant capacity of the cell. Previous data in other cell types suggest that hyperglycemia can induce oxidative stress and that this is associated with elevated ROS production (reviewed in Refs. 65 and 66). To determine whether the reduction in GSH caused by exposure to high G/I was associated with increased production of ROS, the adipocytes were preloaded with DCF and intensity of fluorescence quantified as described under "Experimental Procedures." DCF fluorescence is a measure of ROS formation and oxidative stress (54, 67). Incubation with high G/I increased fluorescence intensity in a time-dependent manner. A significant increase was observed after 3 h of exposure, which peaked by 5 h at 203 ± 23% of control (p < 0.05, n = 4) (Fig. 6). NAC inhibited the increase in fluorescence (106 ± 23% of control). Exposure of adipocytes to 100 mM H2O2, a positive control, augmented fluorescence to 162 ± 11% of control (p < 0.05) (Fig. 7).


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 7.   Effect of high glucose and insulin on ROS generation in adipocytes. Rat adipocytes were prepared as described and incubated in DMEM containing 5.6 mM glucose (Control), 15 mM glucose and 10-7 M insulin (High G/I), 15 mM glucose and 10-7 M insulin with NAC (High G/I + NAC), or with 100 mM H2O2 (H2O2). The adipocytes were loaded with 20 µM DCF-DA at time 0. After 1, 3, and 5 h, the cells were washed, resuspended in PBS, and fluorescence intensity measured as described under "Experimental Procedures." A, representative distribution of log fluorescence intensity of 10,000 cells from one of three experiments with similar results. Rightward shift indicates the presence of increased ROS. B, the mean ± S.E. of the peak fluorescence intensities after 5 h relative to control (100%) are shown (n = 4). *, p < 0.05 compared with control and 15 mM glucose and 10-7 M insulin + NAC. The increase in fluorescence intensity induced by 15 mM glucose and 10-7 M insulin peaked at 5 h (data not shown) whereas that caused by H2O2 declined gradually from 1 to 5 h.

Effect of High G/I, BSO, and NAC on the Vanadyl EPR Signal-- As outlined above, intracellular GSH participates in the reduction of vanadate to vanadyl. Thus, it was postulated that in the adipocytes cultured under conditions that resulted in diminished GSH concentration, which was accompanied by enhanced sensitivity of glucose uptake, there would be decreased conversion of vanadate to vanadyl. It is known that vanadyl (+4), but not vanadate (+5), is detected by EPR spectroscopy because it contains an unpaired electron (68). Therefore, the EPR signal intensities reflect the amounts of vanadyl (+4) present in the different cell preparations. After the 18-h culture under the conditions described above, adipocytes were washed and exposed to 1 mM vanadate for 2 h. Equal aliquots of cells were transferred to capillary tubes, rapidly frozen to -50 °C, and subjected to EPR spectroscopy as described under "Experimental Procedures." BSO treatment as well as exposure to high G/I decreased the intensity of the vanadyl EPR signal compared with control (Fig. 8A). This was 39 ± 8% of control in BSO-treated and 47 ± 5% in high G/I-treated cells (p < 0.05 for both) (Fig. 8B). Pretreatment of the insulin-resistant (high G/I) adipocytes with NAC resulted in a vanadyl signal that was similar to control (114 ± 14%) (Fig. 8).


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 8.   Electron paramagnetic resonance spectroscopy of vanadate-loaded adipocytes: effect of high glucose/insulin, BSO, and NAC. Rat adipocytes were prepared and cultured for 18 h at 37 °C in DMEM containing 5.6 mM glucose (control), 15 mM glucose and 10-7 insulin (Resistant, R), resistant cells pretreated for 2 h with 30 mM NAC (R+NAC), and control with 80 µM BSO (BSO). The adipocytes were washed and incubated with 1 mM vanadate for 2 h, and aliquots transferred to capillary tubes, which were rapidly cooled to -50 °C and subjected to EPR spectroscopy as described under "Experimental Procedures." A, the EPR spectra from a representative experiment is shown. B, results shown are the mean ± S.E. relative intensities of spectra determined from three independent experiments (control = 100%). *, p < 0.05 compared with control and resistant cells pretreated for 2 h with 30 mM NAC (see "Results" for details).

Effect of High G/I, BSO, and NAC on Total Intracellular Vanadium-- A possible additional explanation for the enhanced sensitivity of insulin-resistant adipocytes to vanadate was that vanadate uptake was augmented in the adipocytes exposed to high G/I. Thus, total intracellular vanadium was measured by atomic absorption spectroscopy in equal aliquots of lysates of adipocytes that had been incubated for 60-120 min in 1 mM vanadate under the conditions described above. There were no significant differences in total vanadium after 60, 90, or 120 min between control, high G/I-treated, BSO-treated, or NAC-pretreated high G/I-treated adipocytes (Table II). Taken together with the EPR data, these results indicate that there was a greater concentration of the more highly oxidized vanadium in the insulin-resistant adipocytes.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Vanadium uptake in adipocytes
Adipocytes were cultured in DMEM with 5.6 mM glucose (Control), 15 mM glucose and 10-7 M insulin (Resistant), 80 µM BSO and pretreated for 2 h with 30 mM NAC prior to high glucose and insulin (Resistant + NAC). After 18 h at 37 °C, cells were washed and incubated in 3% BSA-KRBH containing 1 mM vanadate. Aliquots were removed at the times indicated, washed, lysed, and total intracellular vanadium determined by atomic absorption spectroscopy as described under "Experimental Procedures."

Inhibition by Vanadate and Vanadyl of Recombinant PTP1B-- To determine directly whether vanadate is a more effective PTP inhibitor than vanadyl, the ability of both forms of vanadium to inhibit tyrosine dephosphorylation was assayed using whole adipocyte lysates and recombinant PTP1B. In preliminary experiments it was determined that solutions of vanadate and vanadyl freshly prepared with N2-treated H2O and buffers remained stable by measuring absorption at 765 nm as described (69). There was no evidence of oxidation of vanadyl to vanadate over at least 45 min (not shown). The solutions were therefore prepared within 30 min of the phosphatase assays, which were of 10-min duration as described under "Experimental Procedures."

In the PTP1B assay using the pp60c-src C-terminal regulatory peptide as substrate, vanadate (+5) showed a greater efficacy (~4-fold) to inhibit the phosphatase compared with vanadyl (+4) (Fig. 9). Thus, the IC50 was 40 ± 1.1 µM for vanadate and 162 ± 1.2 µM for vanadyl (p < 0.001). The sensitivity of PTP1B to inhibition using the IR beta -subunit phosphoregulatory peptide was found to be less compared with the Src peptide. However, the difference between vanadate and vanadyl was similar with greater inhibition achieved by vanadate at submaximal inhibitory concentrations (Fig. 9, inset). In additional experiments using whole adipocyte lysates and PNPP as substrate, similar results were obtained with vanadate being a more effective inhibitor than vanadyl (percentage of inhibition of dephosphorylation by 1 mM vanadate, 75.3 ± 3.92, and by 1 mM vanadyl, 58.6 ± 9.82) (data not shown).


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 9.   Inhibition of PTP1B by vanadate (+5) and vanadyl (+4). Recombinant GST-PTP1B phosphatase activity was assayed using the pp60c-src C-terminal tyrosine-phosphorylated peptide (TSTEPQpYQPGENL) or the IR beta -subunit triple-tyrosine-phosphorylated regulatory peptide (TRDIpYETDpYpYRK) as described under "Experimental Procedures." The reaction was stopped after 10 min at 22 °C by adding Biomol Green reagent and the amount of Pi released quantified by absorbance at 630 nm. Vanadate (+5) () (inset, filled bars) or vanadyl (+4) (open circle ) (inset, empty bars) (0-4 mM) were added as indicated to inhibit phosphatase activity. Values shown for the pp60c-src peptide are mean ± S.E. of three to six experiments and for the IR peptide (inset) a representative of two experiments with similar results. The dose-dependent inhibition by vanadate (+5) was significantly greater than vanadyl (+4). (IC50 for vanadate, 40 ± 1.1 µM, for vanadyl, 162 ± 1.2 µM; p < 0.001).

Since vanadyl can undergo spontaneous oxidation in a neutral pH solution to vanadate, vanadate may be reduced to vanadyl, and both may bind to DTT (69, 70), which was present in the PTP assay buffer, additional experiments were carried out at lower concentrations and without DTT. Recombinant PTP1B remained active at low and absent DTT. There was a gradual increase in the inhibitory efficacy of both vanadate and vanadyl as DTT concentrations were lowered (data not shown). In the absence of DTT, both inhibited PTP1B activity in the nanomolar range. Under these conditions the relative potency of vanadate was even greater than in the presence of DTT, ~6-fold more potent (IC50, 13.6 ± 1.17 nM) than vanadyl (IC50, 83.2 ± 1.15 nM, p < 0.0001) (Fig. 10).


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 10.   PTP1B phosphatase inhibition by vanadate (+5) and vanadyl (+4) in the absence of DTT. The tyrosine phosphatase activity of recombinant PTP1B was assayed as described in Fig. 9 using the pp60c-src phosphopeptide as substrate in the presence and absence of 0-1 mM vanadate (+5) or vanadyl (+4) but in the absence of DTT. Values are mean ± S.E. of three to five separate experiments. The sensitivity of PTP inhibition to vanadate (+5) () was greater than to vanadyl (+4) (open circle ). The two dose-inhibition curves were significantly different (p = 0.0008), and the IC50 value for vanadate (+5) (13.6 ± 1.17 nM) was significantly lower than for vanadyl (+4) (83.2 ± 1.15 nM, p < 0.0001).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The mechanism of the insulin-mimetic effects of vanadium compounds is not completely understood. Although well documented to inhibit PTPs (25, 31, 71), vanadium compounds have been suggested to directly activate tyrosine kinases (72), inhibit glucose-6-phosphatase (73), inhibit protein degradation (74), alter phosphoinositide metabolism (75, 76), and bind to a variety of small molecules, such as ADP, GDP, and NADH (57, 70), which may all in turn influence cell signaling. However, the predominant effect on PTPs and the ability of general Tyr kinase inhibitors to block the insulin-like actions of vanadium (47-49) indicate that PTP inhibition is the primary mechanism. This concept is also supported by our previous observation that peroxovanadium (pervanadate) is a more potent insulin-mimetic agent and a correspondingly more powerful PTP inhibitor (31).

Whether the more oxidized form vanadate (+5) or reduced form, vanadyl (+4) is the more important and relevant insulin-mimetic form in intact cells and in vivo has been controversial (59, 62, 69). Thus, in some studies it was demonstrated that a cytosolic Tyr kinase was activated by vanadate (+5) while vanadyl (+4) directly inhibited receptor Tyr kinases including the IR kinase (59). In a subsequent report, the same group suggested that vanadyl (+4) had unique properties to activate a cytosolic protein-tyrosine kinase and that adipocytes were more sensitive to vanadyl than vanadate (69). The complex chemistry of vanadium in solution and particularly in living cells (57, 70), along with the uncertainty about which Tyr kinase(s) is responsible for the insulin-like bioeffects, has made this a difficult question to resolve.

In this study we found that the dose-dependent stimulation of glucose uptake in adipocytes was paradoxically more sensitive to vanadate in cells rendered insulin-resistant by exposure to high glucose and insulin. The increased sensitivity of glucose uptake was paralleled by an increased sensitivity of IR phosphorylation and Tyr kinase activity. Although the role of the IR in mediating the glucose transport stimulated by vanadate is not clear and the IR may not be the kinase involved, its Tyr phosphorylation serves as a cellular marker of PTP inhibition. Furthermore, we found an enhanced sensitivity of PKB Ser-473 phosphorylation in response to vanadate in the insulin-resistant adipocytes. This Ser kinase has been demonstrated to be a necessary component of the signaling pathway of insulin to stimulate glucose uptake. We noted that the concentrations of vanadate that achieved maximum Ser-473 phosphorylation were higher (~5-10 mM) than those required to achieve maximum IR activation (1 mM). Since vanadate is a nonspecific PTP inhibitor, this observation is consistent with activation of other Tyr kinases and recruitment of additional pools of PKB not activated by insulin. Similar results were observed in muscle cells with pervanadate (50). Taken together, these results are consistent with an enhanced activity of vanadate to inhibit PTPs in insulin-resistant cells.

One possible explanation for the enhanced sensitivity to vanadate could have been an elevated PTP activity in the insulin-resistant cells, since the apparent efficacy of vanadium compounds to mimic insulin depends on PTP activity. However, in this model of insulin resistance, we have recently found that IR-related PTP activity is diminished rather than elevated (77). These findings are in agreement with other in vitro (78) and in vivo (79, 80) studies demonstrating that hyperglycemia-induced insulin resistance is not associated with increased IR Tyr dephosphorylation or PTP activity. An alternative explanation was postulated based on several phenomena.

First, it is known that, upon entering cells, vanadate (+5) is reduced to vanadyl (+4). This may be a mechanism to limit cell toxicity, as vanadate and particularly, pervanadate, have been found to cause oxidative stress (81), DNA damage (82), and induce neoplastic transformation in cultured fibroblasts (83). In the latter study, vanadyl (+4) alone did not induce neoplastic transformation whereas vanadate (+5) had minimal activity. However, depletion of GSH with diethylmaleate sensitized cells to vanadate-induced transformation. These results, combined with the proposal that vanadate (+5) was the major inhibitor of PTPs rather than vanadyl (+4) (see above) suggested that, in our resistant cells, there was decreased reduction of vanadate to vanadyl and/or increased re-oxidation of vanadyl to vanadate. Finally, exposure of various tissues to high concentrations of glucose has been documented to result in oxidative stress (65, 66) and depletion of GSH (84-87).

In the present studies, depletion of GSH with BSO reproduced the leftward shift in the vanadate dose-response curve seen in the insulin-resistant adipocytes. Furthermore, pretreatment of the adipocytes with the antioxidant and GSH precursor, NAC, blocked the enhanced sensitivity caused by the high G/I exposure. To determine whether these perturbations were associated with the predicted changes in vanadate to vanadyl conversion, EPR spectroscopy was performed. This revealed that enhanced vanadate sensitivity was associated with a decreased intensity of the vanadyl (+4) signal. Since total cell-associated vanadium, determined by atomic absorption, was similar under all these conditions, the EPR results indicate that, in the insulin-resistant and BSO-treated cells, there was a greater amount of vanadate (+5). In addition, these data imply that the insulin-resistant cells were under oxidative stress. Measurements of GSH showed that, as expected, BSO markedly depleted intracellular GSH. Exposure to high G/I also significantly decreased GSH, which was prevented by pretreatment with NAC. A decrease in cellular antioxidant concentration is indicative of oxidative stress, which was confirmed by the increased fluorescence intensity of DCF-loaded adipocytes exposed to high G/I. Taken together, these experiments indicate that vanadate (+5) is a more potent PTP inhibitor than vanadyl (+4) and that the increased intracellular vanadate (+5) in insulin-resistant adipocytes explains the paradoxical enhanced sensitivity to vanadate. This conclusion, based on results in intact cells, was confirmed by our in vitro findings, which demonstrated a greater potency of vanadate compared with vanadyl to inhibit recombinant PTP1B, an intracellular PTP shown recently to be a major regulator of IR Tyr dephosphorylation (88-90). The greater efficacy of vanadate is also consistent with its trigonal bipyramidal structure, which resembles phosphate more closely than the tetrahedral geometry of vanadyl (57, 62).

In a recent study, Cuncic et al. (60) reported that cultured Jurkat T-lymphoma cells, which were unresponsive to vanadate, became sensitive to stimulation of protein tyrosine phosphorylation after GSH depletion. Pretreatment of cells with vanadate had no effect on PTP activity of solubilized cell membrane fractions, whereas after GSH depletion ~50% inhibition by vanadate was observed. The authors suggested that the lack of reversibility of PTP inhibition in vitro in the presence of vanadium chelators such as EDTA was consistent with intracellular formation of pervanadate, which was previously demonstrated to cause irreversible inhibition by oxidizing the free PTP sulfhydryl to SO2 (91). Since pervanadate, similar to vanadate, is not paramagnetic and not seen by EPR spectroscopy, we cannot rule out a contribution of de novo generated peroxovanadium to the increased sensitivity to vanadate observed in the adipocytes treated with high glucose. However, given that adipocytes are 500-1000-fold more sensitive to pervanadate than vanadate (31, 92) and considering the magnitude of the differences in sensitivity of glucose uptake and PTP inhibition observed, it is not necessary to invoke a contribution of generated pervanadate to explain our results.

In summary, the greater intrinsic potency of vanadate (+5) compared with vanadyl (+4), especially in the nanomolar range as seen in the absence of DTT, along with the higher ratio of vanadate (+5)/vanadyl (+4) concentrations in the insulin-resistant cells appear adequate to explain the shifts in sensitivity of the biological responses seen in the intact cells.

The use of vanadium compounds to treat diabetes has been successful in rodents (25-28). In people with diabetes and overt hyperglycemia, oral administration of vanadium compounds did result in modest improvement in glucose concentrations (38, 39). However, when administered to subjects with insulin resistance who did not manifest hyperglycemia, vanadate had no significant effect (40). These clinical observations are consistent with a more potent effect of vanadium in the presence of elevated glucose. It is possible that the oxidative stress induced by high glucose may increase sensitivity to vanadate in vivo as we found in isolated cells.

Despite the difficulty in achieving effective circulating concentrations of vanadium in humans, interest in the inhibition of PTP1B and concomitant activation of the IR Tyr kinase remains high, particularly since enhanced insulin sensitivity and resistance to high fat diet-induced insulin resistance was reported in the PTP1B-/- mouse (90). The specificity of vanadium compounds for different PTPs may be amenable to modification by alteration of ligands (92, 93). This study now demonstrates that the relative potency of vanadium may be regulated by intracellular redox state such that increased efficacy may be achieved in tissues under oxidative stress. This property could be utilized as a method to target PTP inhibition to specific tissues.

    ACKNOWLEDGEMENTS

We thank Dr. D. Templeton for help with the atomic absorption spectroscopy, Dr. J. Boggs for advice on EPR, G. Deragon for technical assistance, B. Baubinas for secretarial support, and Drs. C. Yip, S. Grinstein, and D. Crans for helpful discussion.

    FOOTNOTES

* This work was supported by a grant from the Canadian Institutes of Health Research (to I. G. F.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Supported in part by a Banting and Best Center summer studentship.

§ To whom correspondence should be addressed: Mount Sinai Hospital, 600 University Ave., Suite 780, Toronto, Ontario M5G 1X5, Canada. Tel.: 416-586-8665; Fax: 416-586-8785; E-mail: fantus@mshri.on.ca.

Published, JBC Papers in Press, July 19, 2001, DOI 10.1074/jbc.M106783200

    ABBREVIATIONS

The abbreviations used are: IR, insulin receptor; IRS, insulin receptor substrate; PI 3-kinase, phosphatidylinositol 3-kinase; PKB, protein kinase B; PTP, protein-tyrosine phosphatase; 2-DG, 2-deoxyglucose, BSO, buthionine sulfoximine; Tyr(P), phosphotyrosine, WGA, wheat germ agglutinin; ECL, enhanced chemiluminescence; EPR, electron paramagnetic resonance; DCF, dichorofluorescein; DCF-DA, dichorofluorescein-diacetate; NAC, N-acetylcysteine; PNPP, para-nitrophenyl phosphate; DTT, dithiothreitol; GST, glutathione S-transferase; ROS, reactive oxygen species; SH2, Src homology 2; PAGE, polyacrylamide gel electrophoresis; DMEM, Dulbecco's modified Eagle's medium; dd, double distilled; G, gauss; PBS, phosphate-buffered saline; BSA, bovine serum albumin; high G/I, high concentrations of glucose and insulin.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Kahn, C. R. (1994) Diabetes 43, 1066-1084
2. Olefsky, J. M., and Nolan, J. J. (1995) Am. J. Clin. Nutr. 61, 980S-986S
3. Kahn, B. B. (1998) Cell 92, 593-596
4. Taylor, S. I. (1999) Cell 97, 9-12
5. Beck-Nielsen, H., and Groop, L. C. (1994) J. Clin. Invest. 94, 1714-1721
6. O'Doherty, R., Stein, D., and Foley, J. (1997) Diabetologia 40, B10-B15
7. Zierath, J. R., Galuska, D., and Nolte, L. A. (1994) Diabetologia 38, 270-277
8. Ciaraldi, T. P., Kolterman, O. G., Scarlett, J. A., Kao, M., and Olefsky, J. M. (1982) Diabetes 31, 1016-1022
9. Shepherd, P. R., and Kahn, B. B. (1999) N. Engl. J. Med. 341, 248-257
10. Garvey, W. T., Olefsky, J. M., Matthaei, S., and Marshall, S. (1987) J. Biol. Chem. 262, 189-197
11. Traxinger, R. R., and Marshall, S. (1989) J. Biol. Chem. 264, 20910-20916
12. Kashiwagi, A., Verso, M. A., Andrews, J., Vasquez, B., Reaven, G., and Foley, J. E. (1983) J. Clin. Invest. 72, 1246-5124
13. Cheatham, B., and Kahn, C. R. (1995) Endo. Rev. 16, 117-142
14. White, M. F. (1997) Diabetologia 40, S2-S17
15. Holman, G. D., and Kasuga, M. (1997) Diabetologia 40, 991-1003
16. Myers, M. G., Jr., Backer, J. M., Sun, X. J., Shoelson, S., Hu, P., Schlessinger, J., Yoakim, M., Schaffhausen, B., and White, M. F. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 10350-10354
17. Rameh, L. E., and Cantley, L. C. (1999) J. Biol. Chem. 274, 8347-8350
18. Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R., Reese, C. B., and Cohen, P. (1997) Curr. Biol. 7, 261-269
19. Stephens, L., Anderson, K., Stokoe, D., Erdjument-Bromage, H., Painter, G. F., Holmes, A. B., Gaffney, P. R., Reese, C. B., McCormick, F., Tempst, P., Coadwell, J., and Hawkins, P. T. (1998) Science 279, 710-714
20. Kohn, A. D., Summers, S. A., Birnbaum, M. J., and Roth, R. A. (1996) J. Biol. Chem. 271, 31372-31378
21. Le Good, J. A., Ziegler, W. H., Parekh, D. B., Alessi, D. R., Cohen, P., and Parker, P. J. (1998) Science 281, 2042-2045
22. Wang, Q., Somwar, R,., Bilan, P. J., Liu, Z., Jin, J., Woodgett, J. R., and Klip, A. (1999) Mol. Cell. Biol. 19, 4008-4018
23. Bandyopadhyay, G., Standaert, M. L., Zhao, L., Yu, B., Avignon, A., Galloway, L., Karnam, P., Moscat, J., and Farese, R. V. (1997) J. Biol. Chem. 272, 2551-2558
24. Pessin, J. E., Thurmond, D. C., Elmendorf, J. S., Coker, K. J., and Okada, S. (1999) J. Biol. Chem. 274, 2593-2596
25. Shechter, Y. (1990) Diabetes 39, 1-5
26. Orvig, C., Thompson, K. H., Battell, M., and McNeill, J. H. (1995) in Metal Ions in Biological Systems (Sigel, H. , and Sigel, A., eds) , pp. 575-594, Marcel Dekker, Inc., New York
27. Brichard, S. M., and Henquin, J.-C. (1995) Trends Pharmacol. Sci. 16, 265-270
28. Tsiani, E., and Fantus, I. G.,. (1997) Trends Endocrinol. Metab. 8, 51-58
29. Tolman, E. L., Barris, E., Burns, M., Pansini, A., and Partridge, R. (1979) Life Sci. 25, 1159-1164
30. Shechter, Y., and Karlish, S. J. (1980) Nature 284, 556-558
31. Fantus, I. G., Kadota, S., Deragon, G., Foster, B., and Posner, B. I. (1989) Biochemistry 28, 8864-8871
32. Gil, J., Miralpeix, M., Carreras, J., and Bartrons, R. (1988) J. Biol. Chem. 263, 1868-1871
33. Bruck, R., Prigozin, H., Krepel, Z., Rotenberg, P., Shechter, Y., and Bar-Meir, S. (1991) Hepatology 14, 540-544
34. Heyliger, C. E., Tahiliani, A. G., and McNeill, J. H. (1985) Science 227, 1474-1477
35. Brichard, S. M., Assimacopoulos-Jeannet, F., and Jeanrenaud, B. (1992) Endocrinology 131, 311-317
36. Meyerovitch, J., Rothenberg, P., Shechter, Y., Bonner-Weir, S., and Kahn, C. R. (1991) J. Clin. Invest. 87, 1286-1294
37. Brichard, S. M., Okitolonda, W., and Henquin, J. C. (1988) Endocrinology 123, 2048-2053
38. Cohen, N., Halberstam, M., Shlimovich, P., Chang, C. J., Shamoon, H., and Rossetti, L. (1995) J. Clin. Invest. 95, 2501-2509
39. Goldfine, A. B., Simonson, D. C., Folli, F., Patti, M. E., and Kahn, C. R. (1995) J. Clin. Endocrinol. Metab. 80, 3311-3320
40. Halberstam, M., Cohen, N., Shlimovich, P., Rossetti, L., and Shamoon, H. (1996) Diabetes 45, 659-666
41. Green, A. (1986) Biochem. J. 238, 663-669
42. D'Onofrio, F., Le, M. Q., Chiasson, J. L., and Srivastava, A. K. (1994) FEBS Lett. 340, 269-275
43. Pugazhenthi, S., and Khandelwal, R. L. (1993) Mol. Cell. Biochem. 127-128, 211-218
44. Tamura, S., Brown, T. A., Whipple, J. H., Fujita-Yamaguchi, Y., Dubler, R. E., Cheng, K., and Larner, J. (1984) J. Biol. Chem. 259, 6650-6658
45. Fantus, I. G., Ahmad, F., and Deragon, G. (1994) Diabetes 43, 375-383
46. Strout, H. V., Vicario, P. P., Saperstein, R., and Slater, E. E. (1989) Endocrinology 124, 1918-1924
47. Shisheva, A., and Shechter, Y. (1993) J. Biol. Chem. 268, 6463-6469
48. Elberg, G., He, Z., Li, J., Sekar, N., and Shechter, Y. (1997) Diabetes 46, 1684-1690
49. Ida, M., Imai, K., Hashimoto, S., and Kawashima, H. (1996) Biochem. Pharmacol. 51, 1061-1067
50. Tsiani, E., Bogdanovic, E., Sorisky, A., Nagy, L., and Fantus, I. G. (1998) Diabetes 47, 1676-1686
51. Fantus, I. G., Ahmad, F., and Deragon, G. (1990) Endocrinology 127, 2716-2527
52. Olefsky, J. M. (1978) Biochem. J. 172, 137-145
53. Kadota, S., Fantus, I. G., Deragon, G., Guyda, H. J., and Posner, B. I. (1987) J. Biol. Chem. 262, 8252-8256
54. Banki, K., Hutter, E., Colombo, E., Gonchoroff, N. J., and Perl, A. (1996) J. Biol. Chem. 271, 32994-33001
55. Degani, H., Gochin, M., Karlish, S. J., and Shechter, Y. (1981) Biochemistry 20, 5795-5799
56. Macara, I. G., Kustin, K., and Cantley, L. C., Jr. (1980) Biochim. Biophys. Acta 629, 95-106
57. Crans, D. C., Mahroof-Tahir, M., and Keramidas, A. D. (1995) Mol. Cell. Biochem. 153, 17-24
58. Chasteen, N. D., Grady, J. K., and Holloway, C. E. (1986) Inorg. Chem. 25, 2754-2760
59. Elberg, G., Li, J., and Shechter, Y. (1994) J. Biol. Chem. 269, 9521-9527
60. Cuncic, C., Detich, N., Ethier, D., Tracey, A. S., Gresser, M. J., and Ramachandran, C. (1999) J. Biol. Inorg. Chem. 4, 354-359
61. Denu, J. M., Lohse, D. L., Vijayalakshmi, J., Saper, M. A., and Dixon, J. E. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 2493-2498
62. Shaver, A., Ng, J. B., Hall, D. A., and Posner, B. I. (1995) Mol. Cell. Biochem. 153, 5-15
63. Aruoma, O. I., Halliwell, B., Hoey, B. M., and Butler, J. (1989) Free Radic. Biol. Med. 6, 593-597
64. Moldeus, P., and Cotgreave, I. A. (1994) Methods Enzymol. 234, 482-492
65. Wolff, S. P., Jiang, Z. Y., and Hung, J. V. (1991) Free Radic. Biol. Med. 10, 339-352
66. Baynes, J. W. (1991) Diabetes 40405-40412
67. Royall, J. A., and Ischiropoulos, H. (1993) Arch. Biochem. Biophys. 302, 348-355
68. Chasteen, N. D., Lord, E. M., and Thompson, H. J. (1986) in Frontiers in Bioinorganic Chemistry (Xavier, A. V., ed) , pp. 133-141, VCH, Weinheim, Germany
69. Li, J., Elberg, G., Crans, D. C., and Shechter, Y. (1996) Biochemistry 35, 8314-8318
70. Crans, D. C. (1994) Inorg. Chem. 16, 1-33
71. Swarup, G., Speeg, K. V., Jr., Cohen, S., and Garbers, D. L. (1982) J. Biol. Chem. 257, 7298-7301
72. Stankiewicz, P. J., and Tracey, A. S. (1995) in Metal Ions in Biological Systems (Sigel, H. , and Sigel, A., eds) , pp. 249-286b, Marcel Dekker, Inc., New York
73. Schulz, L. O. (1988) Ann. Nutr. Metab. 32, 289-296
74. Fantus, I. G., George, R., Tang, S., Chong, P., and Poznansky, M. J. (1996) Diabetes 45, 1084-1093
75. Atkinson, T. P., Lee, C. W., Rhee, S. G., and Hohman, R. J. (1993) J. Immunol. 151, 1448-1455
76. Blake, R. A., Walker, T. R., and Watson, S. P. (1993) Biochem. J. 290, 471-475
77. Tang, S., Le-Tien, H., Goldstein, B., Shin, P., Lai, R., and Fantus, I. G. (2001) Diabetes 50, 83-90
78. Kroder, G., Bossenmaier, B., Kellerer, M., Capp, E., Stoyanov, B., Muhlhofer, A., Berti, L., Horikoshi, H., Ullrich, A., and Haring, H. (1996) J. Clin. Invest. 97, 1471-1477
79. Kusari, J., Kenner, K. A., Suh, K. I., Hill, D. E., and Henry, R. R. (1994) J. Clin. Invest. 93, 1156-1162
80. Worm, D., Vinten, J., Staehr, P., Henriksen, J. E., Handberg, A., and Beck-Nielsen, H. (1996) Diabetologia 39, 1208-1214
81. Krejsa, C. M., Nadler, S. G., Esselstyn, J. M., Kavanagh, T. J., Ledbetter, J. A., and Schieven, G. L. (1997) J. Biol. Chem. 272, 11541-11549
82. Hiort, C., Goodisman, J., and Dabrowiak, J. C. (1996) Biochemistry 35, 12354-12362
83. Sabbioni, E., Pozzi, G., Devos, S., Pintar, A., Casella, L., and Fischbach, M. (1993) Carcinogenesis 14, 2565-2568
84. Kashiwagi, A., Asahina, T., Ikebuchi, M., Tanaka, Y., Takagi, Y., Nishio, Y., Kikkawa, R., and Shigeta, Y. (1994) Diabetologia 37, 264-269
85. Takayuki, A., Atsunori, K., Yoshihiko, N., Motoyoshi, I., Natsuki, H., Yasushi, T., Yoshihumi, T., Yukikazu, S., Ryuichi, K., and Yukio, S. (1995) Diabetes 44, 520-526
86. Ceriello, A., dello Russo, P., Amstad, P., and Cerutti, P. (1996) Diabetes 45, 471-477
87. Trocino, R. A., Akazawa, S., Ishibashi, M., Matsumoto, K., Matsuo, H., Yamamoto, H., Goto, S., Urata, Y., Kondo, T., and Nagataki, S. (1995) Diabetes 44, 992-998
88. Kenner, K. A., Anyanwu, E., Olefsky, J. M., and Kusari, J. (1996) J. Biol. Chem. 271, 19810-19816
89. Seely, B. L., Staubs, P. A., Reichart, D. R., Berhanu, P., Milarski, K. L., Saltiel, A. R., Kusari, J., and Olefsky, J. M. (1996) Diabetes 45, 1379-1385
90. Elchebly, M., Payette, P., Michaliszyn, E., Cromlish, W., Collins, S., Lee-Loy, A., Normandin, D., Cheng, A., Himms-Hagen, J., Chan, C.-C., Ramachandran, C., Gresser, M. J., Tremblay, M. L., and Kennedy, B. P. (1999) Science 283, 1544-1548
91. Huyer, G., Liu, S., Kelly, J., Moffat, J., Payette, P., Kennedy, B., Tsaprailis, G., Gresser, M. J., and Ramachandran, C. (1997) J. Biol. Chem. 272, 843-851
92. Posner, B. I., Faure, R., Burgess, J. W., Bevan, A. P., Lachance, D., Zhang-Sun, G., Fantus, I. G., Ng, J. B., Hall, D. A., Lum, B. S., and Shaver, A. (1994) J. Biol. Chem. 269, 4596-4604
93. McNeill, J. H., Yuen, V. G., Dai, S., and Orvig, C. (1995) Mol. Cell. Biochem. 153, 175-180


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
Y. Lin, A. H. Berg, P. Iyengar, T. K. T. Lam, A. Giacca, T. P. Combs, M. W. Rajala, X. Du, B. Rollman, W. Li, et al.
The Hyperglycemia-induced Inflammatory Response in Adipocytes: THE ROLE OF REACTIVE OXYGEN SPECIES
J. Biol. Chem., February 11, 2005; 280(6): 4617 - 4626.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
C. A. Haber, T. K. T. Lam, Z. Yu, N. Gupta, T. Goh, E. Bogdanovic, A. Giacca, and I. G. Fantus
N-acetylcysteine and taurine prevent hyperglycemia-induced insulin resistance in vivo: possible role of oxidative stress
Am J Physiol Endocrinol Metab, October 1, 2003; 285(4): E744 - E753.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
I. Talior, M. Yarkoni, N. Bashan, and H. Eldar-Finkelman
Increased glucose uptake promotes oxidative stress and PKC-{delta} activation in adipocytes of obese, insulin-resistant mice
Am J Physiol Endocrinol Metab, August 1, 2003; 285(2): E295 - E302.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
A. Tardif, N. Julien, J.-L. Chiasson, and L. Coderre
Stimulation of glucose uptake by chronic vanadate pretreatment in cardiomyocytes requires PI 3-kinase and p38 MAPK activation
Am J Physiol Endocrinol Metab, June 1, 2003; 284(6): E1055 - E1064.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/38/35589    most recent
M106783200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lu, B.
Right arrow Articles by Fantus, I. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lu, B.
Right arrow Articles by Fantus, I. G.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement